Skip to content

NASCENT BIOTECH, INC.: 10-Q filed 2017-02-09

What NASCENT BIOTECH, INC. reported in its quarterly report filed 2017-02-09 (fiscal Q3 2017): 28 published measures, 73 facts as tagged in accession 0001477932-17-000635.

This filing

Form
10-Q (quarterly report)
Filed
2017-02-09
Fiscal period
fiscal Q3 2017
Accession
0001477932-17-000635 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NASCENT BIOTECH, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-12-31879,590USD
At 2016-03-311,401,314USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-12-31193,915USD
At 2016-03-312,970,093USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-12-31685,675USD
At 2016-03-31-1,568,779USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-12-3191,178USD
At 2016-03-31573,350USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-567,815USD92
2016-04-01 to 2016-12-311,600,782USD275
2015-10-01 to 2015-12-31-339,225USD92
2015-04-01 to 2015-12-31-3,404,267USD275

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2016-04-01 to 2016-12-31-482,422USD275
2015-04-01 to 2015-12-31-736,370USD275

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2016-04-01 to 2016-12-313,000,000USD275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2016-04-01 to 2016-12-31250USD275
2015-04-01 to 2015-12-31635,250USD275

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-12-31-8,779,445USD
At 2016-03-31-10,380,227USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2016-10-01 to 2016-12-3121,860,645shares92
2016-04-01 to 2016-12-3121,771,827shares275
2015-10-01 to 2015-12-3121,075,310shares92
2015-04-01 to 2015-12-3119,260,191shares275

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2016-10-01 to 2016-12-3121,860,645shares92
2016-04-01 to 2016-12-3123,200,144shares275
2015-10-01 to 2015-12-3121,075,310shares92
2015-04-01 to 2015-12-3119,260,191shares275

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-0.03USD/shares92
2016-04-01 to 2016-12-310.07USD/shares275
2015-10-01 to 2015-12-31-0.02USD/shares92
2015-04-01 to 2015-12-31-0.18USD/shares275

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-0.03USD/shares92
2016-04-01 to 2016-12-310.07USD/shares275
2015-10-01 to 2015-12-31-0.02USD/shares92
2015-04-01 to 2015-12-31-0.18USD/shares275

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2016-04-01 to 2016-12-31-240,000USD275

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-04-01 to 2016-12-3125,782USD275
2015-04-01 to 2015-12-313,758,672USD275

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-10-01 to 2016-12-31569,754USD92
2016-04-01 to 2016-12-311,891,805USD275
2015-10-01 to 2015-12-31-265,676USD92
2015-04-01 to 2015-12-31-3,273,536USD275

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-12-3191,178USD
At 2016-03-31573,350USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-04-01 to 2016-12-3154,129USD275
2015-10-01 to 2015-12-3175,102USD92
2015-04-01 to 2015-12-31135,379USD275

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-12-31193,915USD
At 2016-03-312,970,093USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2016-12-31176,036USD
At 2016-06-301,500,000USD
At 2016-03-312,339,244USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2016-04-01 to 2016-12-313,000,000USD275

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2016-10-01 to 2016-12-31196,247USD92
2016-04-01 to 2016-12-311,106,315USD275
2015-10-01 to 2015-12-31225,196USD92
2015-04-01 to 2015-12-314,179,284USD275

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-10-01 to 2016-12-31373,507USD92
2016-04-01 to 2016-12-31481,528USD275
2015-10-01 to 2015-12-3140,480USD92
2015-04-01 to 2015-12-31667,902USD275

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-12-3121,878,415shares
At 2016-03-3121,617,565shares

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-567,815USD92
2016-04-01 to 2016-12-311,840,782USD275
2015-10-01 to 2015-12-31-339,225USD92
2015-04-01 to 2015-12-31-3,404,267USD275

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2016-10-01 to 2016-12-311,939USD92
2016-04-01 to 2016-12-31-51,023USD275
2015-10-01 to 2015-12-31-73,549USD92
2015-04-01 to 2015-12-31-130,731USD275

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2015-04-01 to 2015-12-31695,000USD275

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2016-04-01 to 2016-12-31-479,648USD275

Inspect the source

Entity
NASCENT BIOTECH, INC. / CIK 0001622057
Captured
SEC response SHA-256
95dd35525b286efc227d01e79a7497c1e5ad706dcc5db0f6b86a7f03d8b13612

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001622057.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))